{
    "nctId": "NCT05529862",
    "briefTitle": "Trans-RosaLEE Study: a Biomarker-directed, Translational Study",
    "officialTitle": "Trans-RosaLEE Study: a Biomarker-directed, Translational Study of High-throughput Molecular Profiling of HR+/HER2- Metastatic Breast Cancer Treated With Endocrine Therapy and Ribociclib.",
    "overallStatus": "RECRUITING",
    "conditions": "Advanced or Metastatic Breast Cancer (BC)",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 241,
    "primaryOutcomeMeasure": "Molecular alterations post- versus pre-treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients included in the RosaLEE study.\n2. Patients having read and signed the ICF relative to Trans-RosaLEE.\n3. Tumour material: primary and/or metastatic tumour sample, either available as frozen and collected within 3 months before V0, or newly collected before ribociclib + ET treatment initiation.\n\n   Brain metastases and non-osteolytic bone metastases will be considered as non-collectable/biopsable.\n4. Patient affiliated to the national \"Social Security\" regimen or beneficiary of this regimen.\n\nExclusion Criteria:\n\n1. Not enrolled in RosaLEE.\n2. Brain metastasis and non-osteolytic bone metastases as only metastatic sites, if no available frozen tumour sample already collected within 3 months before V0.\n3. Tumour material not collected before ribociclib + ET initiation.\n4. Person subject to a legal protection measure (adult under guardianship, curatorship or safeguard of justice), or unable to give their consent.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}